GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II: Immune Presentation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002504 describes the biological process by which antigen-presenting cells display peptide or polysaccharide antigens on their surface in association with MHC class II protein complexes.
• MHC class II molecules are loaded with antigenic peptides in endosomal compartments, a process tightly regulated by invariant chain (CD74), HLA-DM, and HLA-DO.
• This pathway is essential for CD4+ T cell activation and the initiation of adaptive immune responses against pathogens and tumors.
• Dysregulation of MHC class II antigen presentation is linked to autoimmune diseases, immunodeficiencies, and cancer immune evasion.
• Key genes include HLA-DRA, HLA-DRB1, CD74, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, and the transcription factor CIITA.
• CRISPR knockout, knock-in, and overexpression models enable functional dissection of MHC class II antigen presentation in human and mouse cells.
Description
Antigen processing and presentation via MHC class II is a central mechanism of adaptive immunity, enabling CD4+ T lymphocytes to recognize extracellular pathogens and initiate appropriate effector responses. The Gene Ontology term GO:0002504 specifically refers to the process in which an antigen-presenting cell expresses peptide or polysaccharide antigen on its cell surface in association with an MHC class II protein complex. This process is distinct from MHC class I presentation, which primarily samples intracellular antigens for CD8+ T cells. Understanding GO:0002504 is critical for immunologists studying host defense, autoimmunity, and cancer immunology, as well as for researchers developing vaccines and immunotherapies. The pathway involves coordinated trafficking of MHC class II molecules, antigen uptake, proteolytic processing, peptide loading, and surface presentation. Recent advances in CRISPR gene editing and functional genomics have accelerated the discovery of novel regulators of this pathway.
antigen processing and presentation of peptide or polysaccharide antigen via MHC class II At A Glance
| GO ID | GO:0002504 |
|---|---|
| GO term | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II |
| Ontology | biological_process |
| Synonym | peptide or polysaccharide antigen processing and presentation of via MHC class II |
| Major function | Surface presentation of peptide or polysaccharide antigens on MHC class II for CD4+ T cell recognition |
| Cellular location | Endosomal compartments, lysosomes, plasma membrane |
| Key molecules | MHC class II (HLA-DR, HLA-DP, HLA-DQ), invariant chain (CD74), HLA-DM, HLA-DO |
| Upstream regulator | CIITA (MHC class II transactivator) |
| Associated diseases | Autoimmunity, immunodeficiency, cancer |
What Is GO:0002504?
GO:0002504 is defined as the process in which an antigen-presenting cell expresses antigen (peptide or polysaccharide) on its cell surface in association with an MHC class II protein complex. This biological process encompasses the intracellular trafficking, proteolytic processing, and loading of antigenic peptides onto MHC class II molecules, followed by their transport to the plasma membrane for recognition by CD4+ T cells.
Why Is antigen processing and presentation of peptide or polysaccharide antigen via MHC class II Important in Cell Biology?
GO:0002504 is fundamental to adaptive immunity because it governs the activation of CD4+ T helper cells, which orchestrate antibody responses, cytotoxic T cell activity, and immune memory. Defects in this pathway cause severe immunodeficiency, while overactivation contributes to autoimmune pathology. Moreover, tumors frequently downregulate MHC class II antigen presentation to evade immune detection, making this process a key target for cancer immunotherapy.
• Essential for CD4+ T cell activation and adaptive immune responses.
• Critical for host defense against extracellular pathogens and parasites.
• Dysregulation leads to autoimmune diseases such as rheumatoid arthritis and type 1 diabetes.
• Loss of function causes bare lymphocyte syndrome and severe immunodeficiency.
• Tumor cells often silence MHC class II to escape CD4+ T cell surveillance.
• Target for vaccine design and immunomodulatory therapies.
• Key pathway for understanding cross-presentation and antigen delivery.
• Regulated by the master transcription factor CIITA.
• Involved in graft rejection and transplant immunology.
• Provides a model for studying endosomal trafficking and proteolysis.
What Happens During antigen processing and presentation of peptide or polysaccharide antigen via MHC class II?
Antigen uptake and endosomal trafficking
In simple terms: The cell engulfs antigens from outside and delivers them to internal compartments.
Antigen-presenting cells such as dendritic cells, macrophages, and B cells internalize extracellular antigens via phagocytosis, macropinocytosis, or receptor-mediated endocytosis. These antigens are delivered to endosomal compartments where they are progressively acidified and exposed to proteases. This step is essential for subsequent peptide generation and loading onto MHC class II molecules.
MHC class II synthesis and invariant chain association
In simple terms: Newly made MHC class II proteins are protected by a chaperone called invariant chain until they reach the right compartment.
MHC class II alpha and beta chains are synthesized in the endoplasmic reticulum and associate with the invariant chain (CD74), which prevents premature peptide binding and directs the complex to endosomal compartments. The invariant chain also contains sorting signals that target the complex to the MHC class II compartment (MIIC).
Proteolytic processing and peptide loading
In simple terms: Enzymes chop antigens into small pieces and load them onto MHC class II molecules.
In the endosomal compartments, cathepsins degrade the invariant chain, leaving a class II-associated invariant chain peptide (CLIP) in the peptide-binding groove. HLA-DM catalyzes the exchange of CLIP for high-affinity antigenic peptides derived from the internalized antigens. HLA-DO modulates HLA-DM activity in B cells and thymic epithelium.
Surface presentation and CD4+ T cell recognition
In simple terms: The loaded MHC class II molecules travel to the cell surface to show the antigen to helper T cells.
Peptide-loaded MHC class II complexes are transported to the plasma membrane via tubular endosomal vesicles. There, they present the antigen to CD4+ T cells bearing cognate T cell receptors, leading to T cell activation, cytokine production, and proliferation. This interaction is central to the initiation of adaptive immune responses.
Key Genes Involved in GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
The following genes encode the major protein components and regulators of MHC class II antigen processing and presentation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-DRA | MHC class II alpha chain | Core component of the peptide-binding heterodimer |
| HLA-DRB1 | MHC class II beta chain | Most polymorphic MHC class II gene; linked to autoimmunity |
| HLA-DPA1 | MHC class II alpha chain (DP) | Antigen presentation in diverse cell types |
| HLA-DPB1 | MHC class II beta chain (DP) | Associated with immune responses and transplantation |
| HLA-DQA1 | MHC class II alpha chain (DQ) | Risk locus for celiac disease and type 1 diabetes |
| HLA-DQB1 | MHC class II beta chain (DQ) | Autoimmune disease susceptibility |
| CD74 | Invariant chain | Chaperone and sorting receptor for MHC class II |
| HLA-DMA | HLA-DM alpha chain | Peptide editing and CLIP removal |
| HLA-DMB | HLA-DM beta chain | Peptide exchange catalyst |
| HLA-DOA | HLA-DO alpha chain | Modulator of HLA-DM in B cells |
| HLA-DOB | HLA-DO beta chain | Regulates peptide loading in B cells |
| CIITA | MHC class II transactivator | Master transcriptional regulator of MHC class II genes |
| CTSB | Cathepsin B | Proteolytic processing of invariant chain and antigens |
| CTSS | Cathepsin S | Degradation of invariant chain in endosomes |
| LGMN | Legumain | Antigen processing in endolysosomes |
| IFI30 | GILT | Reduction of disulfide bonds in antigens |
| CD4 | T cell co-receptor | Binds MHC class II during T cell activation |
How Is antigen processing and presentation of peptide or polysaccharide antigen via MHC class II Regulated?
MHC class II antigen presentation is primarily regulated at the transcriptional level by the MHC class II transactivator CIITA, which is induced by interferon-gamma and controls expression of HLA-DR, HLA-DP, HLA-DQ, and accessory genes. Post-translationally, invariant chain processing and peptide loading are controlled by cathepsins and HLA-DM/HLA-DO. Additionally, signaling through Toll-like receptors and cytokines modulates antigen uptake and endosomal trafficking.
antigen processing and presentation of peptide or polysaccharide antigen via MHC class II and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HLA-DRB1 | Rheumatoid arthritis, type 1 diabetes | Knock-in of risk alleles in human cell lines |
| CIITA | Bare lymphocyte syndrome | Knockout in primary fibroblasts or iPSCs |
| CD74 | Autoimmunity, cancer | Knockout in dendritic cell lines |
| HLA-DMA | Immunodeficiency, autoimmunity | Point mutation knock-in in B cell lines |
| HLA-DQB1 | Celiac disease | Overexpression in antigen-presenting cells |
Autoimmune diseases
Polymorphisms in HLA-DRB1, HLA-DQA1, and HLA-DQB1 are strongly associated with autoimmune conditions such as rheumatoid arthritis, type 1 diabetes, and celiac disease, where aberrant MHC class II presentation of self-antigens drives pathogenic CD4+ T cell responses.
Immunodeficiency
Mutations in CIITA, RFXANK, RFX5, or RFXAP cause bare lymphocyte syndrome, a severe combined immunodeficiency characterized by absent MHC class II expression and defective CD4+ T cell development.
Cancer immune evasion
Many tumors downregulate MHC class II molecules or components of the antigen processing machinery to avoid CD4+ T cell recognition, contributing to immune escape and resistance to immunotherapy.
Infectious diseases
Pathogens such as Chikungunya virus can disrupt antigen presentation pathways, including MHC class I and potentially MHC class II, to evade immune detection.
From antigen processing and presentation of peptide or polysaccharide antigen via MHC class II-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CD74 affect MHC class II surface presentation? | CD74 knockout in human monocyte-derived dendritic cells |
| How does a disease-associated HLA-DRB1 variant alter peptide binding? | Point mutation knock-in in HLA-DRB1-null B cell line |
| Can CIITA overexpression restore MHC class II in tumor cells? | CIITA overexpression in melanoma cell lines |
| What is the role of HLA-DM in peptide editing? | HLA-DMA/HLA-DMB double knockout in B cells |
| Does tagging endogenous HLA-DRA reveal trafficking dynamics? | Tagged knock-in of HLA-DRA with fluorescent protein |
| Which genes regulate MHC class II antigen presentation? | Genome-wide CRISPR knockout library screening in antigen-presenting cells |
How to Study the antigen processing and presentation of peptide or polysaccharide antigen via MHC class II Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface and intracellular MHC class II levels | Phenotyping antigen-presenting cells |
| Immunopeptidomics | Peptide repertoire bound to MHC class II | Antigen discovery and vaccine design |
| CRISPR knockout screening | Gene essentiality for MHC class II presentation | Discovery of novel regulators |
| Confocal microscopy | Subcellular localization and trafficking | Endosomal dynamics of MHC class II |
| Western blot | Protein expression of MHC class II components | Validation of knockout or overexpression |
| ELISPOT | Antigen-specific T cell activation | Functional readout of presentation |
| RNA-seq | Transcriptional profiling of MHC class II genes | CIITA-dependent regulation studies |
Flow cytometry and immunophenotyping
Flow cytometry using antibodies against HLA-DR, HLA-DP, HLA-DQ, and CD74 allows quantification of surface and intracellular MHC class II expression in antigen-presenting cells.
Proteomics and immunopeptidomics
Mass spectrometry-based immunopeptidomics identifies peptides eluted from MHC class II molecules, revealing the repertoire of presented antigens and the impact of genetic perturbations.
CRISPR screening
Genome-wide CRISPR knockout or activation screens coupled with MHC class II surface staining or T cell activation readouts can identify novel regulators of GO:0002504.
Imaging and trafficking assays
Live-cell imaging of fluorescently tagged MHC class II and invariant chain enables visualization of endosomal trafficking and peptide loading in real time.
How CRISPR Can Be Used to Study GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
Knockout
CRISPR knockout of genes such as CD74, HLA-DMA, HLA-DMB, or CIITA in antigen-presenting cell lines abolishes or severely impairs MHC class II antigen presentation, providing causal evidence for their function.
Point Mutation
Introducing disease-associated point mutations in HLA-DRB1 or HLA-DQB1 via CRISPR base editing or homology-directed repair allows assessment of allele-specific effects on peptide binding and T cell activation.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous HLA-DRA or CD74 loci enables tracking of protein trafficking and interaction partners under physiological expression levels.
Overexpression
CRISPR activation or lentiviral overexpression of CIITA or MHC class II genes can restore antigen presentation in tumor cells or enhance immunogenicity for vaccine studies.
How EDITGENE Supports antigen processing and presentation of peptide or polysaccharide antigen via MHC class II Research
Researchers studying antigen processing and presentation of peptide or polysaccharide antigen via MHC class II-related genes often need to determine whether a candidate gene is causally involved in antigen presentation, immune activation, or disease pathogenesis. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for antigen processing and presentation of peptide or polysaccharide antigen via MHC class II research.
Frequently Asked Questions About antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
What is antigen processing and presentation of peptide or polysaccharide antigen via MHC class II?
It is the biological process (GO:0002504) in which antigen-presenting cells display peptide or polysaccharide antigens on their surface via MHC class II molecules to activate CD4+ T cells.
What genes are involved in MHC class II antigen presentation?
Key genes include HLA-DRA, HLA-DRB1, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, CD74, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, and CIITA.
How does MHC class II antigen presentation differ from MHC class I?
MHC class II presents extracellular antigens to CD4+ T cells, while MHC class I presents intracellular peptides to CD8+ T cells.
What diseases are associated with defects in MHC class II antigen presentation?
Defects cause bare lymphocyte syndrome and immunodeficiency, while dysregulation is linked to autoimmunity and cancer immune evasion.
What is the role of CD74 in MHC class II presentation?
CD74, the invariant chain, chaperones MHC class II molecules, prevents premature peptide binding, and directs them to endosomal compartments.
How is MHC class II expression regulated?
CIITA is the master transcriptional regulator, induced by interferon-gamma, controlling expression of MHC class II genes.
What experimental methods study MHC class II antigen presentation?
Flow cytometry, immunopeptidomics, CRISPR screening, imaging, and T cell activation assays are commonly used.
Can CRISPR be used to study MHC class II antigen presentation?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models enable functional dissection of pathway genes.
What is the role of HLA-DM in antigen presentation?
HLA-DM catalyzes the exchange of CLIP for high-affinity antigenic peptides on MHC class II molecules.
Why is MHC class II antigen presentation important for cancer immunotherapy?
Tumors often downregulate MHC class II to evade CD4+ T cell responses, and restoring presentation can enhance anti-tumor immunity.
Conclusion
GO:0002504 encompasses the essential biological process of MHC class II-mediated antigen presentation, a cornerstone of adaptive immunity and immune surveillance. Its precise regulation by CIITA, invariant chain, and HLA-DM ensures appropriate CD4+ T cell activation, while its dysregulation underlies autoimmunity, immunodeficiency, and cancer. Continued research using CRISPR-based models and functional genomics will further illuminate this pathway and inform therapeutic strategies.
References
- 1. Roche PA et al.. 2015. The ins and outs of MHC class II-mediated antigen processing and presentation.. Nat Rev Immunol 15(4):203-16 PMID: 25720354
- 2. Neefjes J et al.. 2011. Towards a systems understanding of MHC class I and MHC class II antigen presentation.. Nat Rev Immunol 11(12):823-36 PMID: 22076556
- 3. Pishesha N et al.. 2022. A guide to antigen processing and presentation.. Nat Rev Immunol 22(12):751-764 PMID: 35418563
- 4. Zhou F. 2009. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation.. Int Rev Immunol 28(3-4):239-60 PMID: 19811323
- 5. Blander JM et al.. 2023. The show and tell of cross-presentation.. Adv Immunol 159:33-114 PMID: 37996207
- 7. Helft J et al.. 2015. GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells.. Immunity 42(6):1197-211 PMID: 26084029
- 8. Ware BC et al.. 2024. Chikungunya virus infection disrupts MHC-I antigen presentation via nonstructural protein 2.. PLoS Pathog 20(3):e1011794 PMID: 38483968
